New drug combo to shrink bile duct cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) to shrink bile duct or gallbladder tumors enough so they can be surgically removed. It is for people who have not had any prior treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct or gallbladder cancer that has not been treated before and a surgeon thinks it may be removable.
- You should be between 18 and 75 years old.
- You must be in good enough health to be up and about (able to do light work or more).
- No prior chemotherapy, immunotherapy, or other cancer treatments for this condition.
- You cannot have other serious medical conditions like uncontrolled infections, heart problems, or bleeding disorders.
- If you are sexually active, you must agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
This trial tests combining two drugs (adebrelimab and lenvatinib) with a liver-directed chemotherapy infusion (HAIC) to shrink locally advanced bile duct or gallbladder cancers enough to allow surgery. It is for people who haven't had prior treatment for their biliary cancer and whose cancer has not spread far.
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy (GemOX) and lenvatinib can shrink tumors enough so that bile duct or gallbladder cancers that could not be removed initially become eligible for surgery. It is an option for people with advanced but not yet spread cancer who have not received prior treatment.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.